S&P 500   3,855.36
DOW   30,960.00
QQQ   328.11
S&P 500   3,855.36
DOW   30,960.00
QQQ   328.11
S&P 500   3,855.36
DOW   30,960.00
QQQ   328.11
S&P 500   3,855.36
DOW   30,960.00
QQQ   328.11
Log in
NYSE:ITGR

Integer Competitors

$78.15
-0.90 (-1.14 %)
(As of 01/25/2021 12:00 AM ET)
Add
Compare
Today's Range
$77.09
Now: $78.15
$78.92
50-Day Range
$76.27
MA: $80.38
$83.30
52-Week Range
$46.01
Now: $78.15
$99.95
Volume153,813 shs
Average Volume156,268 shs
Market Capitalization$2.57 billion
P/E Ratio35.52
Dividend YieldN/A
Beta1.42

Competitors

Integer (NYSE:ITGR) Vs. ABT, MDT, SYK, ISRG, BDX, and EW

Should you be buying ITGR stock or one of its competitors? Companies in the sub-industry of "health care equipment" are considered alternatives and competitors to Integer, including Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton, Dickinson and (BDX), and Edwards Lifesciences (EW).

Integer (NYSE:ITGR) and Abbott Laboratories (NYSE:ABT) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability and risk.

Risk & Volatility

Integer has a beta of 1.42, suggesting that its stock price is 42% more volatile than the S&P 500. Comparatively, Abbott Laboratories has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500.

Earnings and Valuation

This table compares Integer and Abbott Laboratories' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Integer$1.26 billion2.04$96.34 million$4.6816.70
Abbott Laboratories$31.90 billion6.37$3.69 billion$3.2435.41

Abbott Laboratories has higher revenue and earnings than Integer. Integer is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Integer and Abbott Laboratories, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Integer01302.75
Abbott Laboratories121302.75

Integer currently has a consensus price target of $99.3333, indicating a potential upside of 27.11%. Abbott Laboratories has a consensus price target of $115.6875, indicating a potential upside of 0.84%. Given Integer's higher possible upside, analysts plainly believe Integer is more favorable than Abbott Laboratories.

Institutional and Insider Ownership

96.5% of Integer shares are held by institutional investors. Comparatively, 72.6% of Abbott Laboratories shares are held by institutional investors. 2.2% of Integer shares are held by insiders. Comparatively, 1.7% of Abbott Laboratories shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Integer and Abbott Laboratories' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Integer6.45%9.29%4.52%
Abbott Laboratories10.50%18.19%8.29%

Summary

Abbott Laboratories beats Integer on 8 of the 13 factors compared between the two stocks.

Integer (NYSE:ITGR) and Medtronic (NYSE:MDT) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, risk and valuation.

Volatility & Risk

Integer has a beta of 1.42, suggesting that its stock price is 42% more volatile than the S&P 500. Comparatively, Medtronic has a beta of 0.7, suggesting that its stock price is 30% less volatile than the S&P 500.

Valuation and Earnings

This table compares Integer and Medtronic's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Integer$1.26 billion2.04$96.34 million$4.6816.70
Medtronic$28.91 billion5.44$4.79 billion$4.5925.47

Medtronic has higher revenue and earnings than Integer. Integer is trading at a lower price-to-earnings ratio than Medtronic, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations for Integer and Medtronic, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Integer01302.75
Medtronic032012.92

Integer currently has a consensus price target of $99.3333, indicating a potential upside of 27.11%. Medtronic has a consensus price target of $122.2963, indicating a potential upside of 4.62%. Given Integer's higher possible upside, equities research analysts clearly believe Integer is more favorable than Medtronic.

Institutional & Insider Ownership

96.5% of Integer shares are held by institutional investors. Comparatively, 79.2% of Medtronic shares are held by institutional investors. 2.2% of Integer shares are held by company insiders. Comparatively, 0.5% of Medtronic shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Integer and Medtronic's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Integer6.45%9.29%4.52%
Medtronic12.69%9.71%5.30%

Summary

Medtronic beats Integer on 10 of the 15 factors compared between the two stocks.

Integer (NYSE:ITGR) and Stryker (NYSE:SYK) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, risk and valuation.

Institutional & Insider Ownership

96.5% of Integer shares are held by institutional investors. Comparatively, 71.5% of Stryker shares are held by institutional investors. 2.2% of Integer shares are held by company insiders. Comparatively, 6.8% of Stryker shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent recommendations for Integer and Stryker, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Integer01302.75
Stryker271412.58

Integer currently has a consensus price target of $99.3333, indicating a potential upside of 27.11%. Stryker has a consensus price target of $227.4783, indicating a potential downside of 5.04%. Given Integer's stronger consensus rating and higher possible upside, equities research analysts clearly believe Integer is more favorable than Stryker.

Volatility & Risk

Integer has a beta of 1.42, suggesting that its stock price is 42% more volatile than the S&P 500. Comparatively, Stryker has a beta of 0.87, suggesting that its stock price is 13% less volatile than the S&P 500.

Profitability

This table compares Integer and Stryker's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Integer6.45%9.29%4.52%
Stryker12.35%20.94%8.77%

Valuation and Earnings

This table compares Integer and Stryker's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Integer$1.26 billion2.04$96.34 million$4.6816.70
Stryker$14.88 billion6.05$2.08 billion$8.2629.00

Stryker has higher revenue and earnings than Integer. Integer is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

Summary

Stryker beats Integer on 11 of the 15 factors compared between the two stocks.

Intuitive Surgical (NASDAQ:ISRG) and Integer (NYSE:ITGR) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, analyst recommendations, valuation and risk.

Institutional & Insider Ownership

86.5% of Intuitive Surgical shares are owned by institutional investors. Comparatively, 96.5% of Integer shares are owned by institutional investors. 1.6% of Intuitive Surgical shares are owned by insiders. Comparatively, 2.2% of Integer shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Intuitive Surgical and Integer, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Intuitive Surgical381002.33
Integer01302.75

Intuitive Surgical presently has a consensus target price of $736.0588, indicating a potential downside of 2.12%. Integer has a consensus target price of $99.3333, indicating a potential upside of 27.11%. Given Integer's stronger consensus rating and higher possible upside, analysts clearly believe Integer is more favorable than Intuitive Surgical.

Risk & Volatility

Intuitive Surgical has a beta of 0.98, meaning that its share price is 2% less volatile than the S&P 500. Comparatively, Integer has a beta of 1.42, meaning that its share price is 42% more volatile than the S&P 500.

Profitability

This table compares Intuitive Surgical and Integer's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Intuitive Surgical24.45%12.08%10.44%
Integer6.45%9.29%4.52%

Earnings and Valuation

This table compares Intuitive Surgical and Integer's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Intuitive Surgical$4.48 billion19.74$1.38 billion$9.9575.58
Integer$1.26 billion2.04$96.34 million$4.6816.70

Intuitive Surgical has higher revenue and earnings than Integer. Integer is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Summary

Intuitive Surgical beats Integer on 9 of the 14 factors compared between the two stocks.

Becton, Dickinson and (NYSE:BDX) and Integer (NYSE:ITGR) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, analyst recommendations, valuation and risk.

Institutional & Insider Ownership

83.2% of Becton, Dickinson and shares are owned by institutional investors. Comparatively, 96.5% of Integer shares are owned by institutional investors. 0.8% of Becton, Dickinson and shares are owned by insiders. Comparatively, 2.2% of Integer shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Becton, Dickinson and and Integer, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Becton, Dickinson and07702.50
Integer01302.75

Becton, Dickinson and presently has a consensus target price of $279.6667, indicating a potential upside of 7.46%. Integer has a consensus target price of $99.3333, indicating a potential upside of 27.11%. Given Integer's stronger consensus rating and higher possible upside, analysts clearly believe Integer is more favorable than Becton, Dickinson and.

Risk & Volatility

Becton, Dickinson and has a beta of 0.79, meaning that its share price is 21% less volatile than the S&P 500. Comparatively, Integer has a beta of 1.42, meaning that its share price is 42% more volatile than the S&P 500.

Profitability

This table compares Becton, Dickinson and and Integer's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Becton, Dickinson and5.11%13.30%5.60%
Integer6.45%9.29%4.52%

Earnings and Valuation

This table compares Becton, Dickinson and and Integer's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Becton, Dickinson and$17.12 billion4.42$874 million$10.2025.51
Integer$1.26 billion2.04$96.34 million$4.6816.70

Becton, Dickinson and has higher revenue and earnings than Integer. Integer is trading at a lower price-to-earnings ratio than Becton, Dickinson and, indicating that it is currently the more affordable of the two stocks.

Summary

Becton, Dickinson and beats Integer on 8 of the 14 factors compared between the two stocks.

Edwards Lifesciences (NYSE:EW) and Integer (NYSE:ITGR) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, analyst recommendations, valuation and risk.

Institutional & Insider Ownership

80.9% of Edwards Lifesciences shares are owned by institutional investors. Comparatively, 96.5% of Integer shares are owned by institutional investors. 1.5% of Edwards Lifesciences shares are owned by insiders. Comparatively, 2.2% of Integer shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Edwards Lifesciences and Integer, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Edwards Lifesciences271202.48
Integer01302.75

Edwards Lifesciences presently has a consensus target price of $90.8704, indicating a potential upside of 5.80%. Integer has a consensus target price of $99.3333, indicating a potential upside of 27.11%. Given Integer's stronger consensus rating and higher possible upside, analysts clearly believe Integer is more favorable than Edwards Lifesciences.

Risk & Volatility

Edwards Lifesciences has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500. Comparatively, Integer has a beta of 1.42, meaning that its share price is 42% more volatile than the S&P 500.

Profitability

This table compares Edwards Lifesciences and Integer's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Edwards Lifesciences18.18%29.00%18.10%
Integer6.45%9.29%4.52%

Earnings and Valuation

This table compares Edwards Lifesciences and Integer's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Edwards Lifesciences$4.35 billion12.31$1.05 billion$1.8646.18
Integer$1.26 billion2.04$96.34 million$4.6816.70

Edwards Lifesciences has higher revenue and earnings than Integer. Integer is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

Summary

Edwards Lifesciences beats Integer on 8 of the 14 factors compared between the two stocks.


Integer Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Abbott Laboratories logo
ABT
Abbott Laboratories
2.4$114.72-1.6%$203.33 billion$31.90 billion60.70Upcoming Earnings
Medtronic logo
MDT
Medtronic
2.7$116.90-0.3%$157.35 billion$28.91 billion44.62
Stryker logo
SYK
Stryker
2.0$239.55-0.2%$90.02 billion$14.88 billion51.96Upcoming Earnings
Intuitive Surgical logo
ISRG
Intuitive Surgical
1.7$752.01-1.1%$88.40 billion$4.48 billion85.65Earnings Announcement
Becton, Dickinson and logo
BDX
Becton, Dickinson and
2.0$260.24-0.6%$75.69 billion$17.12 billion95.33Dividend Announcement
News Coverage
Edwards Lifesciences logo
EW
Edwards Lifesciences
1.6$85.89-0.4%$53.53 billion$4.35 billion68.71Upcoming Earnings
Boston Scientific logo
BSX
Boston Scientific
2.2$36.78-0.7%$52.67 billion$10.74 billion14.09
IDEXX Laboratories logo
IDXX
IDEXX Laboratories
1.5$489.21-0.7%$41.73 billion$2.41 billion85.23Upcoming Earnings
Baxter International logo
BAX
Baxter International
2.3$80.10-0.7%$40.92 billion$11.36 billion45.51
DexCom logo
DXCM
DexCom
1.9$376.39-1.7%$36.14 billion$1.48 billion155.53Insider Selling
ResMed logo
RMD
ResMed
1.4$221.68-2.8%$32.12 billion$2.96 billion47.57Upcoming Earnings
Hologic logo
HOLX
Hologic
1.9$76.34-0.8%$19.62 billion$3.78 billion18.18Upcoming Earnings
Insulet logo
PODD
Insulet
1.3$288.91-0.5%$19.05 billion$738.20 million656.63
Teleflex logo
TFX
Teleflex
2.0$382.14-1.1%$17.80 billion$2.60 billion49.18
STERIS logo
STE
STERIS
2.1$190.41-0.9%$16.25 billion$3.03 billion38.62Upcoming Earnings
Varian Medical Systems logo
VAR
Varian Medical Systems
1.3$175.33-0.1%$16.02 billion$3.17 billion59.84
Abiomed logo
ABMD
Abiomed
1.5$348.32-0.1%$15.74 billion$840.88 million76.55Upcoming Earnings
Masimo logo
MASI
Masimo
1.4$257.09-2.6%$14.15 billion$937.84 million66.78
Hill-Rom logo
HRC
Hill-Rom
2.0$101.16-1.7%$6.71 billion$2.88 billion30.47
Globus Medical logo
GMED
Globus Medical
1.4$64.44-1.4%$6.36 billion$785.37 million70.04
Integra LifeSciences logo
IART
Integra LifeSciences
1.4$69.36-0.1%$5.85 billion$1.52 billion103.52
NuVasive logo
NUVA
NuVasive
1.5$56.80-0.2%$2.91 billion$1.17 billion-258.18
AtriCure logo
ATRC
AtriCure
1.3$58.30-1.3%$2.62 billion$230.81 million-50.70
Cardiovascular Systems logo
CSII
Cardiovascular Systems
1.3$46.51-0.3%$1.87 billion$236.54 million-70.47
Alphatec logo
ATEC
Alphatec
0.8$14.92-0.7%$1.17 billion$113.43 million-13.56
CryoLife logo
CRY
CryoLife
1.5$24.96-1.2%$969.87 million$276.22 million-65.68
Orthofix Medical logo
OFIX
Orthofix Medical
1.2$44.94-2.2%$868.77 million$459.95 million37.45
AngioDynamics logo
ANGO
AngioDynamics
1.6$18.55-1.9%$704.04 million$264.16 million-4.15
Surmodics logo
SRDX
Surmodics
1.5$46.33-1.0%$633.89 million$94.86 million579.13News Coverage
Accuray logo
ARAY
Accuray
2.2$5.08-0.6%$463.67 million$382.93 million36.29Upcoming Earnings
Invacare logo
IVC
Invacare
1.6$9.92-0.1%$341.43 million$927.96 million-8.06
Rockwell Medical logo
RMTI
Rockwell Medical
1.3$1.46-2.7%$136.62 million$61.30 million-3.40
This page was last updated on 1/26/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.